Viking Therapeutics, Inc. (VKTX)
25.37
+0.20
(+0.79%)
USD |
NASDAQ |
Oct 19, 13:59
Viking Therapeutics Cash from Operations (Annual) : -278.68M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -278.68M |
| December 31, 2024 | -87.79M |
| December 31, 2023 | -73.38M |
| December 31, 2022 | -48.40M |
| December 31, 2021 | -47.59M |
| December 31, 2020 | -21.78M |
| December 31, 2019 | -24.75M |
| Date | Value |
|---|---|
| December 31, 2018 | -18.76M |
| December 31, 2017 | -14.76M |
| December 31, 2016 | -11.07M |
| December 31, 2015 | -8.732M |
| December 31, 2014 | -1.591M |
| December 31, 2013 | -0.0782M |
| December 31, 2012 | -0.05M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Eli Lilly & Co. | 16.81B |
| Regeneron Pharmaceuticals, Inc. | 4.979B |
| Vertex Pharmaceuticals, Inc. | 3.631B |
| Ironwood Pharmaceuticals, Inc. | 127.04M |
| Compass Therapeutics, Inc. | -49.14M |